These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21030554)

  • 1. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.
    Jabbour E; Kantarjian H; O'Brien S; Shan J; Garcia-Manero G; Wierda W; Ravandi F; Borthakur G; Rios MB; Cortes J
    Blood; 2011 Feb; 117(6):1822-7. PubMed ID: 21030554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
    Kim DD; Lee H; Kamel-Reid S; Lipton JH
    Br J Haematol; 2013 Mar; 160(5):630-9. PubMed ID: 23278256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
    Kantarjian H; Shah NP; Hochhaus A; Cortes J; Shah S; Ayala M; Moiraghi B; Shen Z; Mayer J; Pasquini R; Nakamae H; Huguet F; Boqué C; Chuah C; Bleickardt E; Bradley-Garelik MB; Zhu C; Szatrowski T; Shapiro D; Baccarani M
    N Engl J Med; 2010 Jun; 362(24):2260-70. PubMed ID: 20525995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.
    Daghistani M; Marin D; Khorashad JS; Wang L; May PC; Paliompeis C; Milojkovic D; De Melo VA; Gerrard G; Goldman JM; Apperley JF; Clark RE; Foroni L; Reid AG
    Blood; 2010 Dec; 116(26):6014-7. PubMed ID: 20855863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.
    Jabbour E; Kantarjian H; Ghanem H; O'Brien S; Quintas-Cardama A; Garcia-Manero G; Cardenas M; Cortes J
    Clin Lymphoma Myeloma Leuk; 2013 Jun; 13(3):302-6. PubMed ID: 23318257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
    Milojkovic D; Nicholson E; Apperley JF; Holyoake TL; Shepherd P; Drummond MW; Szydlo R; Bua M; Foroni L; Reid A; Khorashad JS; de Lavallade H; Rezvani K; Paliompeis C; Goldman JM; Marin D
    Haematologica; 2010 Feb; 95(2):224-31. PubMed ID: 19833633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
    Shah NP; Kim DW; Kantarjian H; Rousselot P; Llacer PE; Enrico A; Vela-Ojeda J; Silver RT; Khoury HJ; Müller MC; Lambert A; Matloub Y; Hochhaus A
    Haematologica; 2010 Feb; 95(2):232-40. PubMed ID: 20139391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience.
    Jabbour E; Cortes J; Nazha A; O'Brien S; Quintas-Cardama A; Pierce S; Garcia-Manero G; Kantarjian H
    Blood; 2012 May; 119(19):4524-6. PubMed ID: 22431574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
    Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
    Falchi L; Kantarjian HM; Wang X; Verma D; Quintás-Cardama A; O'Brien S; Jabbour EJ; Ravandi-Kashani F; Borthakur G; Garcia-Manero G; Verstovsek S; Burger JA; Luthra R; Cortes JE
    Am J Hematol; 2013 Dec; 88(12):1024-9. PubMed ID: 23913852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
    Radich JP; Kopecky KJ; Appelbaum FR; Kamel-Reid S; Stock W; Malnassy G; Paietta E; Wadleigh M; Larson RA; Emanuel P; Tallman M; Lipton J; Turner AR; Deininger M; Druker BJ
    Blood; 2012 Nov; 120(19):3898-905. PubMed ID: 22915637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
    Milojkovic D; Apperley JF; Gerrard G; Ibrahim AR; Szydlo R; Bua M; Reid A; Rezvani K; Foroni L; Goldman J; Marin D
    Blood; 2012 Feb; 119(8):1838-43. PubMed ID: 22174159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response.
    Roy L; Tomowiak C; Guilhot F
    Blood; 2011 Nov; 118(19):5096-8. PubMed ID: 21876122
    [No Abstract]   [Full Text] [Related]  

  • 15. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
    Jabbour E; Kantarjian HM; Saglio G; Steegmann JL; Shah NP; Boqué C; Chuah C; Pavlovsky C; Mayer J; Cortes J; Baccarani M; Kim DW; Bradley-Garelik MB; Mohamed H; Wildgust M; Hochhaus A
    Blood; 2014 Jan; 123(4):494-500. PubMed ID: 24311723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
    Hochhaus A; Müller MC; Radich J; Branford S; Kantarjian HM; Hanfstein B; Rousselot P; Kim DW; Lipton JH; Bleickardt E; Lambert A; Hughes TP
    Leukemia; 2009 Sep; 23(9):1628-33. PubMed ID: 19641527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
    Fujisawa S; Nakamae H; Ogura M; Ishizawa K; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Akiyama H; Onishi S
    Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
    Kantarjian H; O'Brien S; Jabbour E; Shan J; Ravandi F; Kadia T; Faderl S; Garcia-Manero G; Borthakur G; Cortes J
    J Clin Oncol; 2011 Aug; 29(23):3173-8. PubMed ID: 21747082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.
    DeAngelo DJ; Chen L; Guerin A; Styles A; Giguere-Duval P; Wu EQ
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):245-51. PubMed ID: 24393622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Marin D; Ibrahim AR; Lucas C; Gerrard G; Wang L; Szydlo RM; Clark RE; Apperley JF; Milojkovic D; Bua M; Pavlu J; Paliompeis C; Reid A; Rezvani K; Goldman JM; Foroni L
    J Clin Oncol; 2012 Jan; 30(3):232-8. PubMed ID: 22067393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.